Gulbay, GoncaYesilada, ElifErkurt, Mehmet AliBag, Harika GozukaraKuku, IrfanKaya, Emin2024-08-042024-08-0420190250-46851303-829Xhttps://doi.org/10.1515/tjb-2018-0054https://search.trdizin.gov.tr/yayin/detay/340509https://hdl.handle.net/11616/92547Objective: Detection of JAK2 V617F in myeloproliferative neoplasms (MPNs) is very important in both diagnosis and disease progression. In our study, we investigated the frequency of JAK2 V617F mutation in patients with myeloproliferative disorders. Methods: We retrospectively reviewed the records of 720 patients (174 females and 546 males) who were tested for JAK2 V617F mutation from January 2007 to December 2017. Results: In our patients were determined 22.6% JAK2 V617F mutation. 33.3% in women, 19.2% in men have been positive for JAK2 V617F mutation. In our study JAK2 V617F present in 48.6% of essential thrombocythemia, 80.5% of polycythemia rubra vera (PV), 47.5% of primary myelofibrosis, 10% of MPNs, unclassifiable, 0.8% of others. We also investigated the difference in hematological parameters [white blood cell, hemoglobin (Hb), hematocrit (HCT), red blood cell distribution widths (RDW) and platelets count (PLT)] between JAK2 V617F positive and JAK2 V617F negative patients. Conclusions: Investigation of the JAK2 V617F mutation is very important in cases of MPNs. In our study JAK2 V617F mutation was higher in PV, essential thrombocythemia, and primary myelofibrosis patients. However, there were significant differences in Hb, HCT, RDW and PLT levels in mutation-positive patients.eninfo:eu-repo/semantics/openAccessJanus Kinase2JAK-STAT pathwayMyeloproliferative disordersJAK2 V617F mutationReal-time poly-merase chain reactionArticle44449249810.1515/tjb-2018-00542-s2.0-85073555755Q4340509WOS:000489303900010Q4